These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37396621)

  • 1. The Dynamic Intestinal Absorption Model (Diamod®), an
    Moens F; Vandevijver G; De Blaiser A; Larsson A; Spreafico F; Augustijns P; Marzorati M
    Int J Pharm X; 2023 Dec; 5():100177. PubMed ID: 37396621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers.
    Rubbens J; Brouwers J; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2016 Dec; 109():122-129. PubMed ID: 27693678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Interactions Between Bile Salts and Cyclodextrin Cause a Negative Food Effect: Dynamic Dissolution/Permeation Studies with Itraconazole (Sporanox®) and Biomimetic Media.
    Cuoco A; Eriksen JB; Luppi B; Brandl M; Bauer-Brandl A
    J Pharm Sci; 2023 May; 112(5):1372-1378. PubMed ID: 36539063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal behavior of itraconazole in humans - Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution.
    Berben P; Mols R; Brouwers J; Tack J; Augustijns P
    Int J Pharm; 2017 Jun; 526(1-2):235-243. PubMed ID: 28450167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of the Dynamic Intestinal Absorption Model (Diamod) to the Development of a Patient-Centric Drug Formulation.
    Moens F; Larsson A; De Blaiser A; Vandevijver G; Spreafico F; Nicolas JM; Lacombe L; Segregur D; Flanagan T; Berben P
    Mol Pharm; 2023 Dec; 20(12):6197-6212. PubMed ID: 37955627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of oral absorption of cinnarizine--a highly supersaturating poorly soluble weak base with borderline permeability.
    Berlin M; Przyklenk KH; Richtberg A; Baumann W; Dressman JB
    Eur J Pharm Biopharm; 2014 Nov; 88(3):795-806. PubMed ID: 25195981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal behavior of itraconazole in humans - Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution.
    Brouwers J; Geboers S; Mols R; Tack J; Augustijns P
    Int J Pharm; 2017 Jun; 525(1):211-217. PubMed ID: 28414135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linking the concentrations of itraconazole and 2-hydroxypropyl-β-cyclodextrin in human intestinal fluids after oral intake of Sporanox
    Berben P; Stappaerts J; Vink MJA; Domínguez-Vega E; Somsen GW; Brouwers J; Augustijns P
    Eur J Pharm Biopharm; 2018 Nov; 132():231-236. PubMed ID: 29959034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of surfactants, gastric emptying, and dosage form on supersaturation of dipyridamole in an in vitro model simulating the stomach and duodenum.
    Mitra A; Fadda HM
    Mol Pharm; 2014 Aug; 11(8):2835-44. PubMed ID: 25025699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the processes limiting oral drug absorption when amorphous solid dispersions are administered after a high-calorie, high-fat meal: Sporanox® pellets.
    Dietrich S; Dimoula M; Argyropoulos T; Ceulemans J; Goumas K; Vertzoni M; Reppas C
    Eur J Pharm Sci; 2024 Aug; 199():106798. PubMed ID: 38740075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation.
    Berben P; Ashworth L; Beato S; Bevernage J; Bruel JL; Butler J; Dressman J; Schäfer K; Hutchins P; Klumpp L; Mann J; Nicolai J; Ojala K; Patel S; Powell S; Rosenblatt K; Tomaszewska I; Williams J; Augustijns P
    Eur J Pharm Biopharm; 2019 Jul; 140():141-148. PubMed ID: 31051249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT.
    Kourentas A; Vertzoni M; Symillides M; Hens B; Brouwers J; Augustijns P; Reppas C
    Int J Pharm; 2016 Dec; 515(1-2):352-358. PubMed ID: 27732895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential.
    Hens B; Brouwers J; Corsetti M; Augustijns P
    Eur J Pharm Sci; 2015 Sep; 77():40-7. PubMed ID: 26004010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects.
    Hens B; Masuy I; Deloose E; Mols R; Tack J; Augustijns P
    Eur J Pharm Biopharm; 2020 May; 150():66-76. PubMed ID: 32113916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine.
    Holmstock N; De Bruyn T; Bevernage J; Annaert P; Mols R; Tack J; Augustijns P
    Eur J Pharm Sci; 2013 Apr; 49(1):27-32. PubMed ID: 23402972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantage of the Dissolution/Permeation System for Estimating Oral Absorption of Drug Candidates in the Drug Discovery Stage.
    Miyaji Y; Fujii Y; Takeyama S; Kawai Y; Kataoka M; Takahashi M; Yamashita S
    Mol Pharm; 2016 May; 13(5):1564-74. PubMed ID: 27031624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors.
    Madsen CM; Boyd B; Rades T; Müllertz A
    Eur J Pharm Sci; 2016 Aug; 91():31-9. PubMed ID: 27260089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
    Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The artificial membrane insert system as predictive tool for formulation performance evaluation.
    Berben P; Brouwers J; Augustijns P
    Int J Pharm; 2018 Feb; 537(1-2):22-29. PubMed ID: 29241703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of tiny-TIM as a mechanistic tool to investigate the in vitro performance of different itraconazole formulations under physiologically relevant conditions.
    López Mármol Á; Fischer PL; Wahl A; Schwöbel D; Lenz V; Sauer K; Koziolek M
    Eur J Pharm Sci; 2022 Jun; 173():106165. PubMed ID: 35278610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.